Russell Investments Group
CLYM

Russell Investments Group’s Climb Bio CLYM Stock Holding History

Russell Investments Group’s Portfolio CLYM Stock Details CLYM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$37.5K Buy
2,877
+2,798
+3,542% +$28.9K ﹤0.01% 3682
2026
Q1 		$541 Buy
+79
New +$456 ﹤0.01% 4098
2024
Q4 		– Sell
-69
Closed -$351 – 3809
2024
Q3 		$351 Buy
+69
New +$488 ﹤0.01% 3602

Other funds holding CLYM

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $2.7B AUM 88.53% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
FCM
Frontier Capital Management Boston, Massachusetts $10.7B AUM 67.78% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Russell Investments Group's CLYM Position: Q2 2026 in Review

Russell Investments Group increased its Climb Bio (CLYM) stake by 3,542% in Q2 2026, buying an estimated $28.9K and bringing the position to 2,877 shares worth $37.5K. The position accounts for ﹤0.01% of the portfolio, ranked #3682.

Russell Investments Group first reported a position in CLYM in Q3 2024 and has held it in 3 quarters since. 109 funds tracked by Wall St. Rank hold CLYM as of Q2 2026.

  • Russell Investments Group held 2,877 shares of Climb Bio worth $37.5K as of Q2 2026.
  • Russell Investments Group bought 2,798 Climb Bio shares in Q2 2026, an estimated $28.9K.
  • Climb Bio made up ﹤0.01% of Russell Investments Group's portfolio in Q2 2026, its #3682 holding.
  • Russell Investments Group first reported a position in Climb Bio in Q3 2024 and has held it in 3 quarters since.
  • 109 funds tracked by Wall St. Rank held Climb Bio as of Q2 2026.

Based on Russell Investments Group's 13F filing for Q2 2026, filed 6 Aug 2026.